MHC Hammer reveals genetic and non-genetic HLA disruption in cancer evolution

Puttick, C; Jones, TP; Leung, MM; Galvez-Cancino, F; Liu J.L.; Varas-Godoy M.; Rowan A.; Pich O.; Martinez-Ruiz, C; Bentham, R; Dijkstra, KK; Black, JRM; Rosenthal R.; Kanu, N; Litchfield, K; et. al.

Abstract

Disruption of the class I human leukocyte antigen (HLA) molecules has important implications for immune evasion and tumor evolution. We developed major histocompatibility complex loss of heterozygosity (LOH), allele-specific mutation and measurement of expression and repression (MHC Hammer). We identified extensive variability in HLA allelic expression and pervasive HLA alternative splicing in normal lung and breast tissue. In lung TRACERx and lung and breast TCGA cohorts, 61% of lung adenocarcinoma (LUAD), 76% of lung squamous cell carcinoma (LUSC) and 35% of estrogen receptor-positive (ER+) cancers harbored class I HLA transcriptional repression, while HLA tumor-enriched alternative splicing occurred in 31%, 11% and 15% of LUAD, LUSC and ER+ cancers. Consistent with the importance of HLA dysfunction in tumor evolution, in LUADs, HLA LOH was associated with metastasis and LUAD primary tumor regions seeding a metastasis had a lower effective neoantigen burden than non-seeding regions. These data highlight the extent and importance of HLA transcriptomic disruption, including repression and alternative splicing in cancer evolution.

Más información

Título según WOS: MHC Hammer reveals genetic and non-genetic HLA disruption in cancer evolution
Título según SCOPUS: MHC Hammer reveals genetic and non-genetic HLA disruption in cancer evolution
Título de la Revista: Nature Genetics
Volumen: 56
Número: 10
Editorial: Nature Research
Fecha de publicación: 2024
Página de inicio: 2121
Página final: 2131
Idioma: English
DOI:

10.1038/s41588-024-01883-8

Notas: ISI, SCOPUS